Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone in schizophrenia
NCT00088634Phase 2Completed
- Sponsor
- Sumitomo Pharma America
- Start
- May 2004
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Lurasidone with Placebo (2 arms). Primary endpoint: Brief Psychiatric Rating Scale Total Score at 6 weeks. Started May 2004; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00088634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088634.